Inducible epithelial resistance protects mice against leukemia-associated pneumonia.
Despite widespread infection prevention efforts, pneumonia remains the leading cause of death among patients with acute leukemia, due to complex disease- and treatment-dependent immune defects. We have reported that a single inhaled treatment with a synergistic combination of Toll-like receptor 2/6 (TLR 2/6) and TLR9 agonists (Pam2-ODN) induces protective mucosal defenses in mice against a broad range of pathogens. As Pam2-ODN-induced protection persists despite depletion of several leukocyte populations, we tested whether it could prevent pneumonia in a mouse model of acute myeloid leukemia (AML) remission induction therapy. Pam2-ODN prevented death due to pneumonia caused by Pseudomonas aeruginosa, Streptococcus pneumoniae, and Aspergillus fumigatus when mice were heavily engrafted with leukemia cells, had severe chemotherapy-induced neutropenia or both. Pam2-ODN also extended survival of pneumonia in NSG mice engrafted with primary human AML cells. Protection was associated with rapid pathogen killing in the lungs at the time of infection and with reduced pathogen burdens at distant sites at the end of observation. Pathogen killing was inducible directly from isolated lung epithelial cells and was not abrogated by the presence of leukemia cells or cytotoxic agents. Pam2-ODN had no discernible effect on replication rate, total tumor population, or killing by chemotherapy of mouse or human leukemia cells, either in vitro or in vivo. Taken together, we report that therapeutic stimulation of lung epithelial defenses robustly protects against otherwise lethal pneumonias despite the profound immune dysfunction associated with acute leukemia and its treatment. These findings may suggest an opportunity to protect this population during periods of peak vulnerability.
Division of Internal Medicine, Department of Pulmonary Medicine, and.
Miguel M
MM
Leiva-Juárez
Division of Internal Medicine, Department of Pulmonary Medicine, and.
Hayden H
HH
Ware
Division of Internal Medicine, Department of Pulmonary Medicine, and.
Vikram V
VV
Kulkarni
Division of Pediatrics, Department of Leukemia and Lymphoma, University of Texas MD Anderson Cancer Center, Houston, TX; and.
Patrick A
PA
Zweidler-McKay
Division of Internal Medicine, Department of Pulmonary Medicine, and.
Michael J
MJ
Tuvim
Division of Internal Medicine, Department of Pulmonary Medicine, and University of Texas Graduate School of Biomedical Sciences, Houston, TX.
Scott E
0000-0003-4503-0644
SE
Evans
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use; D004847:Epithelial Cells / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D007938:Leukemia / Q000150:complications* / Q000188:drug therapy; D008168:Lung / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology; D011014:Pneumonia / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control*; D012756:Sheep
D000890:Anti-Infective Agents; D009838:Oligodeoxyribonucleotides